Saturday, July 21, 2018 11:42:52 PM
USE OF PROCEEDS
The net proceeds to the Selling Shareholders from the Offering is estimated to be approximately $78,960,000 after deduction of the Underwriters’ Fees. If the Over-Allotment Option is exercised in full, the net proceeds to the Selling Shareholders, after deducting the Underwriters’ Fees will be $90,804,000.
The expenses of the Offering are estimated to be US$800,000. Whether or not the closing of the Offering occurs, all expenses of or incidental to the creation, issue, delivery and marketing of the Offering will be borne by the Company. If the Offering is terminated, other than by reason of a default by one of the Underwriters, the Company will reimburse the Underwriters for any and all expenses reasonably incurred by them, including, for greater certainty, the fees and disbursements of the Underwriters’ legal counsel.
The Company will not receive any proceeds from the Offering. However, the Company believes that the orderly distribution of the Offered Shares sold by the Selling Shareholders is beneficial to the Company and its shareholders, particularly by providing increased liquidity in the Common Shares listed on the TSX and OTCQX, and has therefore agreed to facilitate the Offering under this prospectus.
Recent NB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 04:28:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 10:02:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 10:01:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 10:01:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 10:00:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 10:00:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 09:00:27 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 12/21/2023 09:45:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:55:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 09:30:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 09:30:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 09:30:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 12:30:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2023 09:01:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 12:30:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 12:30:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:30:22 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM